BPC-157

BPC-157 is a linear pentadecapeptide with no disulfide bridges and no fatty-acid conjugation, placing it among the simpler architecturally cytoprotective peptides documented in the literature. Its sequence resists pepsin cleavage and remains stable under acidic gastric conditions — a property that has anchored its use as a model peptide in studies probing cytoprotection mechanisms. Pharmacokinetic descriptors documented in published animal-model investigations include rapid plasma clearance and a short systemic half-life under standard parenteral paradigms. The molecule's interaction profile in the literature touches on nitric-oxide pathway modulation, growth-factor signaling intersection, and angiogenic-marker response in injury-model assays — reported categorically rather than as confirmed mechanisms in human contexts. Structural confirmation of supplied lots is established by mass spectrometry molecular-ion match to the C62H98N16O22 empirical formula, with HPLC-validated purity reported on each Certificate of Analysis.

Experimental domains documented in the published literature include cytoprotective peptide structure-activity studies, gastric mucosal-integrity assays, angiogenic-marker response in tissue-injury rodent models, tendon and ligament fibroblast in-vitro investigations, and signaling intersection with growth-factor and nitric-oxide pathways. Investigators have also characterized BPC-157 in studies of peptide stability under varied buffer conditions and in comparative work alongside other stable cytoprotective fragments. Its use in laboratory research extends to mechanism-elucidation paradigms where the literature frames the molecule as a probe of tissue-response signaling rather than as a defined intervention. The reference standard is supplied for these and equivalent experimental contexts only, with no associated guidance for human, clinical, or veterinary application. Researchers should consult primary literature and institutional review processes for context-specific assay conditions and validated controls.

Each lot of this reference standard is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C62H98N16O22 empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis accompanying every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA also records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material rather than rely on category-level summaries.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.